Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
Status:
Terminated
Trial end date:
2009-02-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the feasibility of giving four weekly doses of
Rituximab (anti-CD20 antibody) in the treatment of children with refractory neuroblastoma
associated opsoclonus-myoclonus. Patients must have continued symptoms of opsoclonus,
myoclonus and or ataxia despite surgical resection and a minimum of one month of steroid
therapy. Evaluations include clinical symptoms of opsoclonus-myoclonus and ataxia as well as
detailed evaluation of learning and development.